
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
DNLI | NASDAQ | USD | Real-time | |
4DN | Frankfurt | EUR | Delayed | |
4DN | TradeGate | EUR | Delayed |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Stacie Weninger | - | 2021 | Member of Scientific Advisory Board |
David P. Schenkein | 68 | 2015 | Independent Director |
David M. Holtzman | - | 2020 | Member of Scientific Advisory Board |
Peter S. Klein | 63 | 2018 | Independent Director |
Steve Edward Krognes | 57 | 2015 | Independent Director |
Marc Tessier-Lavigne | 65 | 2015 | Co-Founder & Independent Director |
Ryan J. Watts | 49 | 2015 | Co-Founder, President, CEO & Director |
Jennifer E. Cook | 59 | 2018 | Independent Director |
Melissa A. Starovasnik | 59 | 2021 | Member of Scientific Advisory Board |
Nancy A. Thornberry | 68 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review